Globus Medical, Inc. with ticker code (GMED) have now 13 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The range between the high target price and low target price is between $100.00 and $55.00 and has a mean share price target at $79.54. (at the time of writing). Given that the stocks previous close was at $73.64 this now indicates there is a potential upside of 8.0%. The day 50 moving average is $71.07 and the 200 moving average now moves to $62.77. The company has a market capitalization of 10.01B. Currently the stock stands at: $73.17 USD
The potential market cap would be $10,806,803,744 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 365.85, revenue per share of $17.13 and a 6.11% return on assets.
Globus Medical, Inc. is a medical device company that develops and commercializes healthcare solutions. The Company’s product categories include Musculoskeletal Solutions and Enabling Technologies. Musculoskeletal Solutions consist primarily of implantable devices, biologics, accessories, and surgical instruments used in a range of spinal, orthopedic and neurosurgical procedures. Its spine products address the majority of conditions affecting the spine, including degenerative conditions, deformity, tumors, and trauma. It provides solutions that facilitate both open and minimally invasive surgery (MIS) techniques. It includes traditional fusion implants, such as pedicle screws and rod systems. Its orthopedic trauma solutions are designed to treat a variety of orthopedic fracture patterns and patient anatomies in the upper and lower extremities, as well as the hip. Enabling Technologies is comprised of imaging, navigation and robotics (INR) solutions for assisted surgery.
